NeoGenomics Inc. Files 8-K on Financials
Ticker: NEO · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1077183
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: NEO
TL;DR
NEO filed an 8-K, looks like standard financial reporting. Keep an eye on the details.
AI Summary
On July 29, 2024, NeoGenomics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates NeoGenomics is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not appear to disclose any immediate negative events or significant changes.
Key Players & Entities
- NEOGENOMICS INC (company) — Registrant
- July 29, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- Fort Myers, Florida (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K filing?
The provided excerpt indicates the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific financial figures.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 29, 2024.
What is NeoGenomics Inc.'s state of incorporation?
NeoGenomics Inc. is incorporated in Nevada.
Where are NeoGenomics Inc.'s principal executive offices located?
NeoGenomics Inc.'s principal executive offices are located at 9490 NeoGenomics Way, Fort Myers, Florida 33912.
What is the SEC file number for NeoGenomics Inc.?
The SEC file number for NeoGenomics Inc. is 001-35756.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-07-29 16:08:46
Key Financial Figures
- $0.001 — ange on which registered Common stock ($0.001 par value) NEO The Nasdaq Stock Market
Filing Documents
- neo-20240729.htm (8-K) — 28KB
- a99-106302024earningsrelea.htm (EX-99.1) — 415KB
- earnings_header002a.jpg (GRAPHIC) — 100KB
- 0001077183-24-000106.txt ( ) — 732KB
- neo-20240729.xsd (EX-101.SCH) — 2KB
- neo-20240729_lab.xml (EX-101.LAB) — 22KB
- neo-20240729_pre.xml (EX-101.PRE) — 13KB
- neo-20240729_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 29, 2024, NeoGenomics, Inc. issued a press release reporting its results for its second fiscal quarter of 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 99.1 Press Release of NeoGenomics, Inc. dated July 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. By: /s/ Jeffrey S. Sherman Name: Jeffrey S. Sherman Title: Chief Financial Officer Date: July 29, 2024